Versigent (VGNT) reported Wednesday the completion of its separation from Aptiv (APTV) and its launch as an independent, publicly traded company.

Versigent shares are expected to start trading on the New York Stock Exchange under the ticker symbol VGNT Wednesday.

The company reported about $8.8 billion in revenue, $528 million in net income, and $893 million in adjusted EBITDA during 2025.

Versigent said it aims to grow top-line revenue by more than 3% and expand EBITDA margins by over 200 basis points over the next three years. It sees a path to $1 billion in free cash flow by 2028.

Aptiv shares were up nearly 11% in premarket activity.